Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01660750 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Criterium.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 5
- Study locations
NCT01660750 is a Phase 1 study of Multiple Myeloma that has completed, run by Criterium. The registered enrollment target is 29 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT01660750, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Criterium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and cyclophosphamide with dexamethasone (Car-Cy-Dex) prior to autologous stem cell transplant (ASCT) in patients with newly diagnosed transplant eligible multiple myeloma.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Dexamethasone
- DRUG Carfilzomib
Study Locations (5)
California
- Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center - Los Angeles
- Comprehensive Cancer Center at Desert Regional Medical Center - Palm Springs
Massachusetts
- University of Massachusettes Memorial - Worcester
North Carolina
- Duke University Medical Center - Durham
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01660750
The ClinicalTrials.gov registry entry for NCT01660750 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The listed sponsor is Criterium, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT01660750 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01660750 about?
NCT01660750 is a clinical study titled "A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma". This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and cyclophosphamide with dexamethasone (Car-Cy-Dex) prior to autologous stem cell transplant (ASCT) in patients with newly diagnosed transplant eligible multiple myel...
What is the current status of trial NCT01660750?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2013-01. Estimated completion is 2015-12.
What conditions does trial NCT01660750 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01660750?
The interventions under investigation include: Cyclophosphamide (DRUG), Dexamethasone (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT01660750?
This trial is sponsored by Criterium, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01660750 being conducted?
This trial has 5 study locations across California, Massachusetts, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.